Efmody^® is a modified-release hydrocortisone therapy that addresses a critical need in the management of congenital adrenal hyperplasia (CAH), offering a new treatment opportunity for patients with this rare genetic condition.

EffRx has obtained from Swissmedic the Marketing Authorization for Efmody® and is currently seeking reimbursement from FOPH to enable the introduction to the market.

The approval and planned market launch of Efmody^® in Switzerland is a testament to EffRx’s commitment to expanding access to essential therapies for rare conditions, and emphasizes its role in transforming patient care in the field of congenital adrenal hyperplasia.